belantamab mafodotin   

GtoPdb Ligand ID: 11117

Synonyms: belantamab mafodotin-blmf | Blenrep® | GSK-2857916 | GSK2857916
belantamab mafodotin is an approved drug (FDA (2020))
Compound class: Antibody
Comment: Belantamab mafodotin (GSK2857916) is a humanised BCMA-targeting antibody-drug conjugate that is in clinical development for multiple myeloma. Mafodotin is the cytotoxic, synthetic antineoplastic monomethyl auristatin F (MMAF; PubChem CID 56841603). Belantamab mafodotin is an IgG1 class antibody so, in addition to its delivery of a cytotoxin, it is predicted to exhibit lytic activity (through complement binding) and/or induce antibody-dependent cell cytotoxicity (ADCC). GlaxoSmithKline claim anti-BCMA ADCs in patent US9273141B2 [1]. SEQ IDs 55 and 63 from US9273141B2 match the full-length heavy chain and light chain sequences respectively, that were submitted to the WHO for the belantamab mafodotin INN.
Classification
Compound class Antibody
Approved drug? Yes (FDA (2020))
International Nonproprietary Names
INN number INN
10754 belantamab mafodotin
Synonyms
belantamab mafodotin-blmf | Blenrep® | GSK-2857916 | GSK2857916
Database Links
Specialist databases
IMGT/mAb-DB 784
Other databases
GtoPdb PubChem SID 434122177
Search PubMed clinical trials belantamab mafodotin
Search PubMed titles belantamab mafodotin
Search PubMed titles/abstracts belantamab mafodotin